Samuraciclib (hydrochloride hydrate)
Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects[1][2].
Product Specifications
Product Name Alternative
CT7001 (hydrochloride hydrate) ; ICEC0942 (hydrochloride hydrate)
UNSPSC
12352005
Target
Apoptosis; CDK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/samuraciclib-hydrochloride-hydrate.html
Purity
99.88
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O[C@H]1CNCC[C@@H]1CNC2=NC3=C(C(C)C)C=NN3C(NCC4=CC=CC=C4)=C2.Cl.O
Molecular Formula
C22H30N6O. (2.5HCl) . (3.7H2O)
Molecular Weight
552.33
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CDK1; CDK2; CDK4; CDK5; CDK6; CDK7; CDK9
Citation 01
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
